Your browser doesn't support javascript.
loading
T-cell recovery and evidence of persistent immune activation 12 months after severe COVID-19.
Taeschler, Patrick; Adamo, Sarah; Deng, Yun; Cervia, Carlo; Zurbuchen, Yves; Chevrier, Stéphane; Raeber, Miro E; Hasler, Sara; Bächli, Esther; Rudiger, Alain; Stüssi-Helbling, Melina; Huber, Lars C; Bodenmiller, Bernd; Boyman, Onur; Nilsson, Jakob.
Afiliación
  • Taeschler P; Department of Immunology, University Hospital Zurich (USZ), Zurich, Switzerland.
  • Adamo S; Department of Immunology, University Hospital Zurich (USZ), Zurich, Switzerland.
  • Deng Y; Department of Immunology, University Hospital Zurich (USZ), Zurich, Switzerland.
  • Cervia C; Department of Immunology, University Hospital Zurich (USZ), Zurich, Switzerland.
  • Zurbuchen Y; Department of Immunology, University Hospital Zurich (USZ), Zurich, Switzerland.
  • Chevrier S; Department of Quantitative Biomedicine, University of Zurich, Zurich, Switzerland.
  • Raeber ME; Institute of Molecular Health Sciences, ETH Zurich, Zurich, Switzerland.
  • Hasler S; Department of Immunology, University Hospital Zurich (USZ), Zurich, Switzerland.
  • Bächli E; Department of Immunology, University Hospital Zurich (USZ), Zurich, Switzerland.
  • Rudiger A; Clinic for Internal Medicine, Hirslanden Klinik St. Anna, Lucerne, Switzerland.
  • Stüssi-Helbling M; Department of Medicine, Limmattal Hospital, Schlieren, Switzerland.
  • Huber LC; Clinic for Internal Medicine, City Hospital Triemli Zurich, Zurich, Switzerland.
  • Bodenmiller B; Clinic for Internal Medicine, City Hospital Triemli Zurich, Zurich, Switzerland.
  • Boyman O; Department of Quantitative Biomedicine, University of Zurich, Zurich, Switzerland.
  • Nilsson J; Institute of Molecular Health Sciences, ETH Zurich, Zurich, Switzerland.
Allergy ; 77(8): 2468-2481, 2022 08.
Article en En | MEDLINE | ID: mdl-35567391
ABSTRACT

BACKGROUND:

T-cell lymphopenia and functional impairment is a hallmark of severe acute coronavirus disease 2019 (COVID-19). How T-cell numbers and function evolve at later timepoints after clinical recovery remains poorly investigated.

METHODS:

We prospectively enrolled and longitudinally sampled 173 individuals with asymptomatic to critical COVID-19 and analyzed phenotypic and functional characteristics of T cells using flow cytometry, 40-parameter mass cytometry, targeted proteomics, and functional assays.

RESULTS:

The extensive T-cell lymphopenia observed particularly in patients with severe COVID-19 during acute infection had recovered 6 months after infection, which was accompanied by a normalization of functional T-cell responses to common viral antigens. We detected persisting CD4+ and CD8+ T-cell activation up to 12 months after infection, in patients with mild and severe COVID-19, as measured by increased HLA-DR and CD38 expression on these cells. Persistent T-cell activation after COVID-19 was independent of administration of a COVID-19 vaccine post-infection. Furthermore, we identified a subgroup of patients with severe COVID-19 that presented with persistently low CD8+ T-cell counts at follow-up and exhibited a distinct phenotype during acute infection consisting of a dysfunctional T-cell response and signs of excessive pro-inflammatory cytokine production.

CONCLUSION:

Our study suggests that T-cell numbers and function recover in most patients after COVID-19. However, we find evidence of persistent T-cell activation up to 12 months after infection and describe a subgroup of severe COVID-19 patients with persistently low CD8+ T-cell counts exhibiting a dysregulated immune response during acute infection.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: COVID-19 / Linfopenia Tipo de estudio: Etiology_studies / Prognostic_studies Límite: Humans Idioma: En Revista: Allergy Año: 2022 Tipo del documento: Article País de afiliación: Suiza

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: COVID-19 / Linfopenia Tipo de estudio: Etiology_studies / Prognostic_studies Límite: Humans Idioma: En Revista: Allergy Año: 2022 Tipo del documento: Article País de afiliación: Suiza